Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Nov 30;13(1):349.
doi: 10.1186/s13256-019-2292-4.

Detection of severe hypertension in a patient with neurofibromatosis type 1 during anesthesia induction: a case report

Juan Wang  1 , Guohua Wei  1 , Zhongyun Wang  1 , He Huang  2
Affiliations
Case Reports

Detection of severe hypertension in a patient with neurofibromatosis type 1 during anesthesia induction: a case report

Juan Wang et al. J Med Case Rep. .

Abstract

Background: Neurofibromatosis type 1 has a higher prevalence of pheochromocytoma and paraganglioma than the general population: 1.0-5.7% versus 0.2-0.6%. Currently, there are no generally accepted guidelines for screening for pheochromocytoma and paragangliomas in asymptomatic patients with neurofibromatosis type 1.

Case presentation: Severe hypertension developed during anesthesia induction in our patient, a 44-year-old Chinese man with neurofibromatosis type 1. We screened for catecholamine level after glioma resection, and the patient was diagnosed with combined pheochromocytoma and paraganglioma.

Conclusions: A delay in diagnosis or lack of a diagnosis in pheochromocytoma and paraganglioma may increase the perioperative morbidity and mortality risk due to excess catecholamine secretion. Therefore, routine pheochromocytoma and paraganglioma screening preoperatively in patients with neurofibromatosis type 1 is very important.

Keywords: Catecholamine; Neurofibromatosis type 1; Pheochromocytoma and paraganglioma; Screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Multiple cutaneous neurofibromata and numerous café-au-lait spots dispersed over the trunk and limbs
Fig. 2
Fig. 2
Enhanced CT of abdomen demonstrated a 7.7 cm × 6.7cm heterogeneous mass in the left adrenal gland (white arrow)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Huson SM. Recent developments in the diagnosis and management of neurofibromatosis. Arch Dis Child. 1989;64:745–749. doi: 10.1136/adc.64.5.745. - DOI - PMC - PubMed
    1. Shinall MC, Solorzano CC. Pheochromocytoma in neurofibromatosis type 1: when should it be suspected? Endocr Pract. 2014;20(8):792–796. doi: 10.4158/EP13417.OR. - DOI - PubMed
    1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF., Jr Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942. doi: 10.1210/jc.2014-1498. - DOI - PubMed
    1. Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young WF, Jr, Bancos I. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clin Endocrinol. 2017;86(1):141–149. doi: 10.1111/cen.13163. - DOI - PubMed
    1. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation of multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51–57. doi: 10.1001/jama.1997.03550010065042. - DOI - PubMed

Publication types